40918-90-9

Basic information

• Product Name: 34DIMETHOXYCINNAMYLALCOHOL
• Synonyms: 34DIMETHOXYCINNAMYLALCOHOL;(E)-3-(3,4-Dimethoxyphenyl)-2-propen-1-ol;E-3',4'-Dimethoxycinnamyl alcohol;trans-3,4-Dimethoxycinnamyl alcohol
• CAS NO: 40918-90-9
• Molecular Formula: C₁₁H₁₄O₃
• Molecular Weight: 194.22706
• Mol File: 40918-90-9.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 348.9±32.0 °C(Predicted)
• Appearance: /
• Density: 1.104±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 14.10±0.10(Predicted)
• CAS DataBase Reference: 34DIMETHOXYCINNAMYLALCOHOL(CAS DataBase Reference)
• NIST Chemistry Reference: 34DIMETHOXYCINNAMYLALCOHOL(40918-90-9)
• EPA Substance Registry System: 34DIMETHOXYCINNAMYLALCOHOL(40918-90-9)

Safety Data

• Hazardous Substances Data: 40918-90-9(Hazardous Substances Data)

Usage

General Description

34DIMETHOXYCINNAMYLALCOHOL is an organic chemical compound with the molecular formula C12H16O3. It is a fragrance ingredient commonly used in perfumes and personal care products for its sweet, floral, and woody scent. This chemical is derived from cinnamyl alcohol, and its structure contains two methoxy groups attached to the cinnamyl moiety. 34DIMETHOXYCINNAMYLALCOHOL is known for its ability to enhance and prolong the scent of fragrances and is also used as a flavoring agent in some food products.

Upstream product

• 93-15-2 1,2-dimethoxy-4-(2-propenyl)benzene 
• 30461-77-9 methyl 3,4-dimethoxycinnamate 
• 20583-78-2 3,4-dimethoxy-cinnamic acid ethyl ester 
• 2316-26-9 3,4-dimethoxycinnamic acid 
• 458-35-5 coniferol 
• 14031-35-7 S-Adenosyl-L-methionine 
• 4497-40-9 3,4-dimethoxy-cinnamaldehyde 
• 120-14-9 3,4-dimethoxy-benzaldehyde 

Downstream Products

• 3929-47-3 3-(3,4-dimethoxyphenyl)-1-propanol 
• 4497-40-9 3,4-dimethoxy-cinnamaldehyde 
• 92632-95-6 3,4-dimethoxycinnamyl chloride 
• 1137837-92-3 tert-butyl (E)-3-(3',4'-dimethoxyphenyl)prop-2-en-1-yl carbonate 
• 3934-86-9 methyl 3,4-dihydroxy-5-methoxybenzoate 
• 73354-15-1 C₂₄H₃₀O₇ 
• 73354-15-1 ((2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl)methyl acetate 
• 73354-15-1 (4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl)methyl acetate 

Relevant articles and documents

Laccase-catalyzed oxidation of allylbenzene derivatives: Towards a green equivalent of ozonolysis

Laccase-based biocatalytic reactions have been tested with and without mediators and optimized in the oxidation of allylbenzene derivatives, such as methyl eugenol taken as a model substrate. The reaction primarily consisted in the hydroxylation of the propenyl side chain, either upon isomerization of the double bond or not. Two pathways were then observed; oxidation of both allylic alcohol intermediates could either lead to the corresponding α,β-unsaturated carbonyl com-pound, or the corresponding benzaldehyde derivative by oxidative cleavage. Such a process consti-tutes a green equivalent of ozonolysis or other dangerous or waste-generating oxidation reactions. The conversion rate was sensitive to the substitution patterns of the benzenic ring and subsequent electronic effects.

Gold-Catalyzed [2,3]-Sigmatropic Rearrangement: Reaction of Aryl Allyl Alcohols with Diazo Compounds

A gold-catalyzed [2,3]-sigmatropic rearrangement reaction has been developed. The intermolecular rearrangement occurs between in situ generated donor-acceptor gold-carbenes and cinnamyl alcohols via tandem oxonium ylide formation. The desired rearranged product has been accomplished selectively over more conventional O-H insertion, cyclopropanation, cycloaddition, and C-H functionalization products under mild, open-air conditions. The scope of the work has been illustrated by synthesizing a new class of substrates that can be used for constructing complex molecular targets.

PHARMACEUTICAL COMPOSITIONS COMPRISING LIGNANS AND THEIR DERIVATIVES FOR TREATING HYPERPLASTIC DISEASES

The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from Leontopodium alpinum Cass. (Edelweiss). A preferred compound is leoligin (=(2S,3R,4R)-4-(3,4-dimethoxybenzyl) -2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl(2Z)-2-methylbut-2-enoat]). Corresponding means and methods in respect of medical uses of the compounds are described. The present invention also provides a medical device comprising, containing or having been contacted with the compound. The compounds provided herein may particularly be used in the treatment of hyperplastic diseases, in particular intimal hyperplasia, e.g. stenosis, restenosis, atherosclerosis and the like. Also envisaged herein is the use of these compounds in the treatment of proliferative diseases, such as leukemia, prostate cancer and lung cancer.